Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Richard Rovin"'
Publikováno v:
PLoS ONE, Vol 19, Iss 7, p e0301739 (2024)
With current imaging, discriminating tumor progression from treatment effect following immunotherapy or oncolytic virotherapy of glioblastoma (GBM) is challenging. A blood based diagnostic biomarker would therefore be helpful. Axl is a receptor tyros
Externí odkaz:
https://doaj.org/article/da9394e7472d483fa852d14f7a212614
Publikováno v:
Breast, Vol 54, Iss , Pp 8-14 (2020)
Background: Due to its rarity, few studies have characterized the epidemiology of male breast cancer. The purpose of this study was to determine survival and risk factors for male breast cancer in a large U.S. population. Methods: In this study, 19,7
Externí odkaz:
https://doaj.org/article/d4106b330e4a4ff6bda906878de6ae14
Autor:
Parvez Akhtar, Daniel Raymond, Melanie Fukui, Samuel Zwernik, Robert Winn, Amber LaCrosse, Brittany Last, Natalie Polinske, Richard Rovin
Publikováno v:
Neuro Oncol
AXL, a member of the TAM family of tyrosine kinases, engages cellular pathways that promote a cancer phenotype. In glioblastoma, increasing AXL expression is associated with worse prognosis. The extracellular domain of AXL is cleaved by the sheddases
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48b8d5d152c555d2eb3ac01993cf6973
https://europepmc.org/articles/PMC7650491/
https://europepmc.org/articles/PMC7650491/
Autor:
Alejandro, Monroy-Sosa, José Omar, Navarro-Fernández, Srikant S, Chakravarthi, Jossana, Rodríguez-Orozco, Richard, Rovin, Jaime, de la Garza, Amin, Kassam
Publikováno v:
Neurosurgical review. 44(3)
The minimally invasive port-based trans-sulcal parafascicular surgical corridor (TPSC) has incrementally evolved to provide a safe, feasible, and effective alternative to access subcortical and intraventricular pathologies. A detailed anatomical foun
Autor:
Sand, Andrea, Duffin, Aspen T., Riddell, Geoffery T., Piacsek, Mitchell, Last, Brittany, Sun, Chaoyang, Richard, Rovin A., Tjoe, Judy A., Yin, Jun
Despite the great improvement of patient outcomes by trastuzumab, a monoclonal antibody targeted on HER2-positive breast cancer, approximately 23% of patients with early-stage disease treated with adjuvant trastuzumab either fail to respond or experi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2986d8bf74649c004a9d8fe4adb6e6ec
https://doi.org/10.1101/2020.01.17.20017947
https://doi.org/10.1101/2020.01.17.20017947
Autor:
Alejandro Monroy-Sosa, Jonathan Jennings, Srikant S Chakravarthi, Melanie B Fukui, Juanita M Celix, Nathaniel Kojis, Mark Lindsay, Richard Rovin, Amin B Kassam
Publikováno v:
Operative Neurosurgery. 16:E75-E77
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.